Published ,
Reading 1 min.
It is the European Medicines Agency (EMA) which announces it on March 29: it is launching the procedure for examining a new vaccine against Covid-19. It was developed by the Spanish multinational Hipra.
The Catalan laboratory Hipra announces that it has developed an anti-covid vaccine, intended to be used as a booster dose after a double vaccination with an mRNA or adenovirus vaccine against Covid-19. According to Hipra, it is called PHH-1V and would be effective against the Omicron variant.
An examination procedure before marketing authorization
It is now in the hands of the European Medicines Agency for a review procedure before potential marketing. Already, the first findings of the EMA are encouraging. She explains in her press release that “preliminary results suggest that the immune response to the Spanish Hipra vaccine may be effective against Sars-CoV-2, including variants of concern such as Omicron”.
An unprecedented technology based on recombinant proteins
The process used for this vaccine is that of recombinant proteins. It combines two specific types of proteins used by the coronavirus to enter host cells in the human body. It is a vaccine “which prepares the body to defend itself” against Covid-19 according to the EMA. The laboratory tests had proved conclusive and the scientists even noted an effectiveness against the Omicron variant.
Consult a GP online
Towards marketing throughout Europe?
EMA says it will assess “data as it becomes available to decide whether the benefits outweigh the risks. Ongoing review will continue until sufficient evidence is available for a formal marketing authorization application.”.
It is not yet known how long this study procedure of this first Spanish vaccine will last. In any case, Hipra must obtain the approval of the EMA before being able to apply for the marketing of its vaccine in the 27 countries of the European Union.